

**RECEIVED  
CENTRAL FAX CENTER****JAN 28 2008**Intarcia Ref. No. 004.10  
USSN 10/004,118  
PATENT**AMENDMENTS TO THE CLAIMS  
(including complete listing of the claims)**

1-85. (Canceled)

86. (Canceled)

87. (Previously Presented) A method of treating hepatitis C (HCV) in a subject in need of such treatment, comprising

administering a therapeutically effective amount of omega interferon protein to the subject, wherein (i) the omega interferon is administered at a controlled rate over time, and (ii) the therapeutically effective amount of omega interferon is an amount of omega interferon selected from the group consisting of between about 48 and about 194 micrograms per week, between about 23 and about 388 micrograms per week, and between about 23 and about 623 micrograms per week.

88. (Previously Presented) A method of treating hepatitis C (HCV) in a subject in need of such treatment, comprising

administering a therapeutically effective amount of omega interferon protein to the subject, wherein (i) the omega interferon is administered by injection, and (ii) the therapeutically effective amount of omega interferon is an amount of omega interferon selected from the group consisting of between about 1 and about 210 micrograms per week and between about 22.5 and about 360 micrograms per week.

89. (Canceled)

90. (Currently Amended) The method of claim ~~8988~~, wherein the therapeutically effective amount of omega interferon is administered by one or more daily injections.

91. (Currently Amended ) The method of claim ~~8988~~, wherein the therapeutically

Intarcia Ref. No. 004.10  
USSN 10/004,118  
PATENT

effective amount of omega interferon is administered by one or more injections given at selected dosing intervals.

92. (Previously Presented) The method of claim 91, wherein the dosing interval comprises three injections per week.

93. (Currently Amended) The method of claim ~~8988~~, wherein the method of injection is selected from the group consisting of subcutaneous injection, intramuscular injection, and bolus intravenous injection.

94. (Previously Presented) The method of claim 93, wherein the omega interferon is administered by subcutaneous injection.

95. (Currently Amended) The method of claim ~~8687~~, wherein the omega interferon is administered by infusion.

96. (Previously Presented) The method of claim 95, wherein the method of infusion is chronic intravascular infusion.

97. (Canceled)

98. (Currently Amended) The method of claim ~~9787~~, wherein a device is used to administer the omega interferon.

99. (Previously Presented) The method of claim 98, wherein the device comprises a pump.

100. (Previously Presented) The method of claim 99, wherein the device is either implanted in or external to the subject.

Intarcia Ref. No. 004.10  
USSN 10/004,118  
PATENT

101. (Previously Presented) The method of claim 100, wherein the device is implanted.

102. (Previously Presented) The method of claim 101, wherein the device comprises an osmotic pump.

103. (Currently Amended) The method of claim 9798, wherein two or more implantable devices are used to administer the omega interferon.

104. (Currently Amended) The method of claim 8688, wherein the therapeutically effective amount of omega interferon is between about 1 and about 210 micrograms per week.

105. (Currently Amended) The method of claim 8688, wherein the therapeutically effective amount of omega interferon is between about 22.5 and about 360 micrograms per week.

106. (Currently Amended) The method of claim 8687, wherein the therapeutically effective amount of omega interferon is between about 23 and about 623 micrograms per week.

107. (Currently Amended) The method of claim 8687, wherein the omega interferon is a recombinant omega interferon.

108. (Previously Presented) An implantable device for use in the method of claim 102, the device comprising

an osmotic pump, and  
a reservoir comprising omega interferon.

109. (Previously Presented) A kit comprising two or more implantable devices for

Intarcia Ref. No. 004.10  
USSN 10/004,118  
PATENT

use in the method of claim 103, wherein the kit comprises at least a first device and a second device, wherein the amount of omega interferon in the first device is less than the amount of omega interferon in the second device.

110. (Previously Presented) The kit of claim 109, wherein the first device comprises a fractional unit-dose of omega interferon and the second device comprises a unit-dose of omega interferon.

111. (Previously Presented) The kit of claim 110, wherein the kit comprises one or more of the first device and one or more of the second device.

112. (Previously Presented) A method of manufacturing the kit of claim 109, comprising

preparing a first device comprising a fractional unit-dose of omega interferon, and  
preparing a second device comprising a unit-dose of omega interferon.

113. (Previously Presented) The method of manufacturing of claim 112, further comprising combining one or more first device with one or more second device in a kit.

114. (New). A method of treating hepatitis C (HCV) in a subject in need of such treatment, comprising

administering a therapeutically effective amount of omega interferon protein to the subject, the administering selected from the group consisting of:

(i) at a controlled rate over time and the therapeutically effective amount of omega interferon is an amount of omega interferon selected from the group consisting of between about 48 and about 194 micrograms per week, between about 23 and about 388 micrograms per week, and between about 23 and about 623 micrograms per week, and

(ii) by injection and the therapeutically effective amount of omega interferon is an amount of omega interferon selected from the group consisting of between about 1 and about 210 micrograms per week and between about 22.5 and about 360 micrograms per week;

Intarcia Ref. No. 004.10  
USSN 10/004,118  
PATENT

wherein the therapeutically effective amount of omega interferon protein is administered over at least about one month.